VYNE Therapeutics Inc. (VYNE)
 NASDAQ: VYNE · Real-Time Price · USD
 0.3664
 +0.0198 (5.71%)
  At close: Oct 30, 2025, 4:00 PM EDT
0.3730
 +0.0066 (1.80%)
  Pre-market: Oct 31, 2025, 4:32 AM EDT
VYNE Therapeutics Revenue
VYNE Therapeutics had revenue of $69.00K in the quarter ending June 30, 2025, a decrease of -65.15%. This brings the company's revenue in the last twelve months to $476.00K, down -2.06% year-over-year. In the year 2024, VYNE Therapeutics had annual revenue of $501.00K with 18.16% growth.
Revenue (ttm) 
 $476.00K
Revenue Growth 
 -2.06%
P/S Ratio 
 32.83
Revenue / Employee 
 $36,615
Employees 
 13
Market Cap 
9.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 501.00K | 77.00K | 18.16% | 
| Dec 31, 2023 | 424.00K | -53.00K | -11.11% | 
| Dec 31, 2022 | 477.00K | -454.00K | -48.76% | 
| Dec 31, 2021 | 931.00K | -20.06M | -95.57% | 
| Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
VYNE News
- 2 months ago - VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga
- 6 months ago - VYNE Therapeutics Provides Update on VYN202 Program - GlobeNewsWire
- 8 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 8 months ago - VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire